Lack of consideration of sex and gender in COVID-19 clinical studies

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Lack of consideration of sex and gender in COVID-19 clinical studies. / Brady, Emer; Nielsen, Mathias Wullum; Andersen, Jens Peter; Oertelt-Prigione, Sabine.

In: Nature Communications, Vol. 12, No. 1, 4015, 12.2021.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Brady, E, Nielsen, MW, Andersen, JP & Oertelt-Prigione, S 2021, 'Lack of consideration of sex and gender in COVID-19 clinical studies', Nature Communications, vol. 12, no. 1, 4015. https://doi.org/10.1038/s41467-021-24265-8

APA

Brady, E., Nielsen, M. W., Andersen, J. P., & Oertelt-Prigione, S. (2021). Lack of consideration of sex and gender in COVID-19 clinical studies. Nature Communications, 12(1), [4015]. https://doi.org/10.1038/s41467-021-24265-8

Vancouver

Brady E, Nielsen MW, Andersen JP, Oertelt-Prigione S. Lack of consideration of sex and gender in COVID-19 clinical studies. Nature Communications. 2021 Dec;12(1). 4015. https://doi.org/10.1038/s41467-021-24265-8

Author

Brady, Emer ; Nielsen, Mathias Wullum ; Andersen, Jens Peter ; Oertelt-Prigione, Sabine. / Lack of consideration of sex and gender in COVID-19 clinical studies. In: Nature Communications. 2021 ; Vol. 12, No. 1.

Bibtex

@article{d156d07e5c0c4304b9891eeac7d6b83d,
title = "Lack of consideration of sex and gender in COVID-19 clinical studies",
abstract = "Sex and gender differences impact the incidence of SARS-CoV-2 infection and COVID-19 mortality. Furthermore, sex differences influence the frequency and severity of pharmacological side effects. A large number of clinical trials to develop new therapeutic approaches and vaccines for COVID-19 are ongoing. We investigated the inclusion of sex and/or gender in COVID-19 studies on ClinicalTrials.gov, collecting data for the period January 1, 2020 to January 26, 2021. Here, we show that of the 4,420 registered SARS-CoV-2/COVID-19 studies, 935 (21.2%) address sex/gender solely in the context of recruitment, 237 (5.4%) plan sex-matched or representative samples or emphasized sex/gender reporting, and only 178 (4%) explicitly report a plan to include sex/gender as an analytical variable. Just eight (17.8%) of the 45 COVID-19 related clinical trials published in scientific journals until December 15, 2020 report sex-disaggregated results or subgroup analyses.",
author = "Emer Brady and Nielsen, {Mathias Wullum} and Andersen, {Jens Peter} and Sabine Oertelt-Prigione",
note = "Funding Information: E.B. and J.P.A. are supported by a grant from the Aarhus University Research Foundation (no. AUFF-F-2018-7-5). Publisher Copyright: {\textcopyright} 2021, The Author(s).",
year = "2021",
month = dec,
doi = "10.1038/s41467-021-24265-8",
language = "English",
volume = "12",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "nature publishing group",
number = "1",

}

RIS

TY - JOUR

T1 - Lack of consideration of sex and gender in COVID-19 clinical studies

AU - Brady, Emer

AU - Nielsen, Mathias Wullum

AU - Andersen, Jens Peter

AU - Oertelt-Prigione, Sabine

N1 - Funding Information: E.B. and J.P.A. are supported by a grant from the Aarhus University Research Foundation (no. AUFF-F-2018-7-5). Publisher Copyright: © 2021, The Author(s).

PY - 2021/12

Y1 - 2021/12

N2 - Sex and gender differences impact the incidence of SARS-CoV-2 infection and COVID-19 mortality. Furthermore, sex differences influence the frequency and severity of pharmacological side effects. A large number of clinical trials to develop new therapeutic approaches and vaccines for COVID-19 are ongoing. We investigated the inclusion of sex and/or gender in COVID-19 studies on ClinicalTrials.gov, collecting data for the period January 1, 2020 to January 26, 2021. Here, we show that of the 4,420 registered SARS-CoV-2/COVID-19 studies, 935 (21.2%) address sex/gender solely in the context of recruitment, 237 (5.4%) plan sex-matched or representative samples or emphasized sex/gender reporting, and only 178 (4%) explicitly report a plan to include sex/gender as an analytical variable. Just eight (17.8%) of the 45 COVID-19 related clinical trials published in scientific journals until December 15, 2020 report sex-disaggregated results or subgroup analyses.

AB - Sex and gender differences impact the incidence of SARS-CoV-2 infection and COVID-19 mortality. Furthermore, sex differences influence the frequency and severity of pharmacological side effects. A large number of clinical trials to develop new therapeutic approaches and vaccines for COVID-19 are ongoing. We investigated the inclusion of sex and/or gender in COVID-19 studies on ClinicalTrials.gov, collecting data for the period January 1, 2020 to January 26, 2021. Here, we show that of the 4,420 registered SARS-CoV-2/COVID-19 studies, 935 (21.2%) address sex/gender solely in the context of recruitment, 237 (5.4%) plan sex-matched or representative samples or emphasized sex/gender reporting, and only 178 (4%) explicitly report a plan to include sex/gender as an analytical variable. Just eight (17.8%) of the 45 COVID-19 related clinical trials published in scientific journals until December 15, 2020 report sex-disaggregated results or subgroup analyses.

UR - http://www.scopus.com/inward/record.url?scp=85109281799&partnerID=8YFLogxK

U2 - 10.1038/s41467-021-24265-8

DO - 10.1038/s41467-021-24265-8

M3 - Journal article

C2 - 34230477

AN - SCOPUS:85109281799

VL - 12

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 4015

ER -

ID: 286328476